HOME >> BIOLOGY >> NEWS
Commercialization deal boosts hope for new sickle-cell drug

A novel once-a-day treatment for sickle-cell disease, based on technology developed at Children's Hospital Boston (CHB) and Beth Israel Deaconess Medical Center (BIDMC), has taken an important step toward the clinic. McNeil Consumer & Specialty Pharmaceuticals and Icagen, Inc., a private biotechnology company, have agreed to jointly develop and commercialize the drug, known as ICA-17043. The agreement follows successful Phase II clinical trials in 90 adults with sickle-cell disease. The companies will collaborate on multicenter Phase III trials, the final step before seeking marketing approval from the U.S. Food and Drug Administration.

Current treatment options are few for sickle-cell disease, a genetic blood disorder that affects millions of children and adults worldwide, including about 70,000 Americans, primarily people of African descent (about 8 percent of African-Americans are carriers). The only approved sickle-cell treatment, developed at CHB 20 years ago, is hydroxyurea. Companies have been slow to invest in additional sickle-cell treatments because the potential market is relatively small. The FDA granted ICA-17043 Orphan Drug Designation in 2000 and Fast Track Status in 2002.

ICA-17043 is related to clotrimazole, an antifungal drug approved in 1975 and long used to treat vaginal yeast infections, jock itch, and athlete's foot. A team led by Dr. Carlo Brugnara, director of the Hematology Laboratory at CHB, discovered in the early 1990s that clotrimazole also reduces sickling of red blood cells.

In sickle cell disease, the body produces an abnormal form of hemoglobin, the compound in red blood cells that carries oxygen. The hemoglobin clumps up and polymerizes forms long rod shapes. This polymerization bends the red cells into sickle-shaped structures, and also causes the cell to lose water. This dehydration, in turn, hardens the cells and promotes sickling by hastening polymerization.

"When
'"/>

Contact: Mary-Ellen Shay
mary.shay@childrens.harvard.edu
617-355-6420
Children's Hospital Boston
3-Aug-2004


Page: 1 2 3

Related biology news :

1. EC boosts European electron microscopy research
2. Bioreactor boosts chemical fermentation by 50 percent: study
3. New genomics tool boosts diabetes research
4. DHEA boosts growth rate of human neural stem cells
5. Marine scientists discover nutrient pollution boosts fungi, bacteria killing Caribbean reefs
6. Sleep boosts ability to learn language, University of Chicago researchers find
7. $13 million grant boosts breast cancer research
8. New national studies show combined hormone replacement therapy boosts stroke, dementia
9. Green tea boosts antimicrobial properties of toothpaste
10. Study boosts confidence in potential screening tool for Alzheimers disease
11. Twenty years of monkey research boosts AIDS knowledge

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
Cached News: